Sudarshan Pharma [SUDARSHAN] vs Styrenix Performance [STYRENIX] Detailed Stock Comparison
Sudarshan Pharma
BSE
Loading...
Styrenix Performance
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Sudarshan Pharma wins in 2 metrics, Styrenix Performance wins in 16 metrics, with 0 ties. Styrenix Performance appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Sudarshan Pharma | Styrenix Performance | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 29.86 | 19.23 | Styrenix Performance |
| Price-to-Book Ratio | 4.76 | 3.72 | Styrenix Performance |
| Debt-to-Equity Ratio | 129.85 | 34.02 | Styrenix Performance |
| PEG Ratio | N/A | -1.27 | N/A |
| EV/EBITDA | 16.49 | 13.91 | Styrenix Performance |
| Profit Margin (TTM) | 3.83% | 7.00% | Styrenix Performance |
| Operating Margin (TTM) | 6.99% | 7.61% | Styrenix Performance |
| EBITDA Margin (TTM) | 6.99% | 7.61% | Styrenix Performance |
| Return on Equity | 12.13% | 20.14% | Styrenix Performance |
| Return on Assets (TTM) | 3.96% | 10.26% | Styrenix Performance |
| Free Cash Flow (TTM) | $304.76M | $-3.82B | Sudarshan Pharma |
| Dividend Yield | N/A | 2.34% | N/A |
| 1-Year Return | -93.27% | -2.95% | Styrenix Performance |
| Price-to-Sales Ratio (TTM) | 1.13 | 1.35 | Sudarshan Pharma |
| Enterprise Value | $7.94B | $46.24B | Styrenix Performance |
| EV/Revenue Ratio | 1.44 | 1.43 | Styrenix Performance |
| Gross Profit Margin (TTM) | 11.05% | 27.12% | Styrenix Performance |
| Revenue per Share (TTM) | $23 | $1,860 | Styrenix Performance |
| Earnings per Share (Diluted) | $0.87 | $128.45 | Styrenix Performance |
| Beta (Stock Volatility) | 0.68 | 0.66 | Styrenix Performance |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Sudarshan Pharma vs Styrenix Performance Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Sudarshan Pharma | 4.99% | 4.88% | -15.13% | -6.93% | -11.29% | -38.71% |
| Styrenix Performance | -1.79% | 4.74% | -4.72% | -22.58% | -5.02% | -18.96% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Sudarshan Pharma | -93.27% | -51.13% | -51.13% | -51.13% | -51.13% | -51.13% |
| Styrenix Performance | -2.95% | 190.19% | 384.27% | 203.33% | 555.22% | 2,066.16% |
News Based Sentiment: Sudarshan Pharma vs Styrenix Performance
Sudarshan Pharma
News based Sentiment: NEGATIVE
Sudarshan Pharma faces significant headwinds, including a substantial year-to-date stock decline, negative analyst ratings predicting a 48% decline, and concerning valuation metrics. While the upcoming IPO presents a potential opportunity, the overall narrative is one of caution and risk, making this a pivotal moment for the company.
Styrenix Performance
News based Sentiment: MIXED
Styrenix reported a mixed bag of results in Q1 FY26, with strong revenue growth offset by declining profitability. The upcoming board meeting and market sentiment analysis add complexity, making this a significant but not entirely positive month for investors.
Performance & Financial Health Analysis: Sudarshan Pharma vs Styrenix Performance
| Metric | SUDARSHAN | STYRENIX |
|---|---|---|
| Market Information | ||
| Market Cap | ₹6.56B | ₹43.54B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 53,200 | 37,062 |
| 90 Day Avg. Volume | 77,333 | 29,629 |
| Last Close | ₹28.63 | ₹2,426.20 |
| 52 Week Range | ₹24.69 - ₹53.50 | ₹2,220.50 - ₹3,498.00 |
| % from 52W High | -46.49% | -30.64% |
| All-Time High | ₹452.70 (Sep 30, 2024) | ₹3,498.00 (Jun 09, 2025) |
| % from All-Time High | -93.68% | -30.64% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.46% | 0.35% |
| Quarterly Earnings Growth | N/A | -0.15% |
| Financial Health | ||
| Profit Margin (TTM) | 0.04% | 0.07% |
| Operating Margin (TTM) | 0.07% | 0.08% |
| Return on Equity (TTM) | 0.12% | 0.20% |
| Debt to Equity (MRQ) | 129.85 | 34.02 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹5.46 | ₹663.93 |
| Cash per Share (MRQ) | ₹0.09 | ₹61.62 |
| Operating Cash Flow (TTM) | ₹8.46M | ₹-3,519,400,000 |
| Levered Free Cash Flow (TTM) | ₹159.55M | ₹2.35B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 2.34% |
| Last 12-Month Dividend | N/A | ₹62.00 |
Valuation & Enterprise Metrics Analysis: Sudarshan Pharma vs Styrenix Performance
| Metric | SUDARSHAN | STYRENIX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 29.86 | 19.23 |
| Forward P/E | N/A | N/A |
| PEG Ratio | N/A | -1.27 |
| Price to Sales (TTM) | 1.13 | 1.35 |
| Price to Book (MRQ) | 4.76 | 3.72 |
| Market Capitalization | ||
| Market Capitalization | ₹6.56B | ₹43.54B |
| Enterprise Value | ₹7.94B | ₹46.24B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.44 | 1.43 |
| Enterprise to EBITDA | 16.49 | 13.91 |
| Risk & Other Metrics | ||
| Beta | 0.68 | 0.66 |
| Book Value per Share (MRQ) | ₹5.46 | ₹663.93 |
Financial Statements Comparison: Sudarshan Pharma vs Styrenix Performance
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SUDARSHAN | STYRENIX |
|---|---|---|
| Revenue/Sales | ₹1.45B | ₹9.44B |
| Cost of Goods Sold | ₹1.29B | ₹6.88B |
| Gross Profit | ₹160.46M | ₹2.56B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹101.60M | ₹717.50M |
| EBITDA | ₹122.50M | ₹998.40M |
| Pre-Tax Income | ₹54.09M | ₹705.40M |
| Income Tax | ₹14.51M | ₹186.20M |
| Net Income (Profit) | ₹39.59M | ₹519.20M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SUDARSHAN | STYRENIX |
|---|---|---|
| Cash & Equivalents | ₹5.51M | ₹976.50M |
| Total Current Assets | ₹3.35B | ₹13.61B |
| Total Current Liabilities | ₹2.60B | ₹6.61B |
| Long-Term Debt | ₹104.60M | ₹3.77B |
| Total Shareholders Equity | ₹1.31B | ₹11.68B |
| Retained Earnings | N/A | ₹7.40B |
| Property, Plant & Equipment | ₹200.50M | ₹8.53B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SUDARSHAN | STYRENIX |
|---|---|---|
| Operating Cash Flow | N/A | ₹251.00M |
| Capital Expenditures | N/A | ₹-380.00M |
| Free Cash Flow | N/A | ₹870.00M |
| Debt Repayment | N/A | ₹-1.15B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SUDARSHAN | STYRENIX |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 53,200 | 37,062 |
| Average Daily Volume (90 Day) | 77,333 | 29,629 |
| Shares Outstanding | 240.66M | 17.59M |
| Float Shares | 71.19M | 8.96M |
| % Held by Insiders | 0.76% | 0.49% |
| % Held by Institutions | 0.00% | 0.12% |
Dividend Analysis & Yield Comparison: Sudarshan Pharma vs Styrenix Performance
| Metric | SUDARSHAN | STYRENIX |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹62.00 |
| Last 12-Month Dividend Yield | N/A | 2.34% |
| 3-Year Avg Annual Dividend | N/A | ₹88.00 |
| 3-Year Avg Dividend Yield | N/A | 3.06% |
| 3-Year Total Dividends | N/A | ₹264.00 |
| Ex-Dividend Date | N/A | Aug 21, 2025 |